Key facts
- Wockhardt's antibiotic ZAYNICH received US FDA approval.
- ZAYNICH is indicated for complicated urinary tract infections.
- The drug targets multidrug-resistant Gram-negative pathogens.
- Phase 3 trials showed strong efficacy for ZAYNICH.
- ZAYNICH has projected peak sales of $1.5 billion.
- Wockhardt's stock surged 19% on the news.
The US FDA approval of Wockhardt's antibiotic, ZAYNICH, is a significant development in the fight against antimicrobial resistance. The drug's indication for complicated urinary tract infections and its efficacy against multidrug-resistant pathogens underscore the growing need for innovative treatments in this area. This approval could position Wockhardt as a key player in addressing a critical global health challenge and potentially transform its financial outlook.